PROF Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Profound Medical Corp (PROF) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows strong growth potential with a bullish technical setup, positive analyst sentiment, and an upcoming catalyst in the form of clinical CAPTAIN data presentation. Despite negative earnings, the company's revenue and net income are improving significantly, making it a promising long-term investment.
The technical indicators show a bullish trend with SMA_5 > SMA_20 > SMA_200, MACD positive and contracting, and RSI in the neutral zone at 55.539. The stock is trading above its pivot point of 6.55, with resistance levels at 7.081 and 7.409, and support levels at 6.019 and 5.691.
Upcoming presentation of clinical CAPTAIN data, considered one of the most important studies in prostate cancer.
Analyst maintains a Buy rating with a $12 price target, indicating significant upside potential.
Revenue growth of 43.13% YoY and improvement in net income by 65.25% YoY.
Gross margin decreased by 5.86% YoY, which could indicate cost pressures.
No significant trading trends from hedge funds or insiders.
In Q4 2025, revenue increased by 43.13% YoY to $5,977,000. Net income improved by 65.25% YoY to -$8,175,000, and EPS improved by 42.11% YoY to -0.27. However, gross margin dropped to 66.77%, down 5.86% YoY.
Lake Street analyst Ben Haynor maintains a Buy rating with a $12 price target, citing the importance of the upcoming clinical CAPTAIN data presentation and undervaluation of the company's enterprise value.
